Loading...
Harrow Health, Inc. 8.625% Senior Notes due 2026
HROWL•NASDAQ
HealthcareMedical - Pharmaceuticals
$25.24
$-0.01(-0.04%)
Harrow Health, Inc. 8.625% Senior Notes due 2026 (HROWL) Stock Overview
Explore Harrow Health, Inc. 8.625% Senior Notes due 2026’s financial performance, market position, analyst ratings, and future outlook.
Stats data is not available for HROWLStats details for HROWL are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for HROWLAnalyst Recommendations details for HROWL are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Company Profile
Harrow, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Pharmaceutical Compounding and Pharmaceutical Drug Development. The Pharmaceutical Compounding segment focuses on the operations of the ImprimisRx business. The company was founded by Mark L. Baum and Robert J. Kammer in January 2006 and is headquartered in Nashville, TN.
CEO
Mark L. Baum
Employees
217
Headquarters
Nashville, DE
Founded
2021